

BRAIN Biotech AG Fact Sheet

→ www.brain-biotech.com/investors

Company Profile

Since the foundation of the company in 1993, BRAIN Biotech AG has developed from an R&D powerhouse to a truly integrated enterprise, which can offer the full value chain from the lab to production. We solely focus on the B2B segment as a solutions provider to the industry.

With our innovative bio-based products and solutions for nutrition, health and the environment, we promote the development of the bioeconomy. We support our industrial customers on their way to sustainable processes and products. Our focus is accordingly on industrial ("white") biotechnology.

Our own R&D and partnered research programs address some of the most prominent topics for a better and healthier life. With our proprietary genome-editing technology we are building a platform to „Edit the Living for the Better.“

Natural-based products enjoy above average growth rates and an ever-increasing consumer interest.



Our **BioScience** business is characterized by year or multi-year service contracts with some of the most renowned brand names in the world. Within our incubator we develop breakthrough innovations for some of the largest societal issues with a focus on health & nutrition.



Our **BioIndustrial** business is largely focused on the high value niche production of enzymes, micro-organisms and natural compounds. We produce with a focus on the less cyclical end-markets of nutrition, health and the environment.

Headquarter and BRAIN Group

BRAIN Biotech AG's headquarter and technology campus are located in Zwingenberg, Germany.

BioScience



BioIndustrial



→ www.brain-biotech.com/brain-group

Sustainability

We develop products and services that change the way of industrial production. Our natural and sustainable bio-based processes accelerate the economic transformation to a circular economy. With our current products and solutions we already directly address at least five UN sustainability goal:



We have published a declaration on the German Sustainability Code.

WE SUPPORT



Since 2021 we proudly support the UN Global Compact.

Stock market listing

BRAIN Biotech AG is listed in the Prime Standard of the Frankfurt Stock Exchange since 9 February, 2016.

Ticker code: BNN


Security code: ISIN DE0005203947 /

WKN 520394

Key figures FY 2021/22:

- Sales: € 49.5 million
- Growth: + 29% (YoY)
- Cash: € 8.4 million
- Adjusted EBITDA: -€ 0.98 million
- Workforce: ~ 330

A Truly International Business



Revenue by region in FY 2021/22

Status as of January 2023